JP2020512283A - コアシェル型マイクロニードル装置及びその使用 - Google Patents
コアシェル型マイクロニードル装置及びその使用 Download PDFInfo
- Publication number
- JP2020512283A JP2020512283A JP2019529985A JP2019529985A JP2020512283A JP 2020512283 A JP2020512283 A JP 2020512283A JP 2019529985 A JP2019529985 A JP 2019529985A JP 2019529985 A JP2019529985 A JP 2019529985A JP 2020512283 A JP2020512283 A JP 2020512283A
- Authority
- JP
- Japan
- Prior art keywords
- peroxide
- insulin
- pva
- glucose
- sensitive linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011258 core-shell material Substances 0.000 title description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 175
- 102000004877 Insulin Human genes 0.000 claims abstract description 87
- 108090001061 Insulin Proteins 0.000 claims abstract description 87
- 229940125396 insulin Drugs 0.000 claims abstract description 87
- 239000003814 drug Substances 0.000 claims abstract description 67
- 238000000034 method Methods 0.000 claims abstract description 58
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 56
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 134
- 239000008103 glucose Substances 0.000 claims description 133
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 127
- 150000002978 peroxides Chemical class 0.000 claims description 113
- 229920000642 polymer Polymers 0.000 claims description 71
- 108010015776 Glucose oxidase Proteins 0.000 claims description 43
- 239000004366 Glucose oxidase Substances 0.000 claims description 43
- 229940116332 glucose oxidase Drugs 0.000 claims description 43
- 235000019420 glucose oxidase Nutrition 0.000 claims description 43
- 210000004369 blood Anatomy 0.000 claims description 33
- 239000008280 blood Substances 0.000 claims description 33
- 102000004190 Enzymes Human genes 0.000 claims description 30
- 108090000790 Enzymes Proteins 0.000 claims description 30
- 229940088598 enzyme Drugs 0.000 claims description 30
- 230000002000 scavenging effect Effects 0.000 claims description 25
- 102000016938 Catalase Human genes 0.000 claims description 24
- 108010053835 Catalase Proteins 0.000 claims description 24
- -1 boronic acid ester Chemical class 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 20
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 19
- 229920002674 hyaluronan Polymers 0.000 claims description 19
- 229960003160 hyaluronic acid Drugs 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 15
- 208000013016 Hypoglycemia Diseases 0.000 claims description 11
- SCHLBXGBHOBSFT-UHFFFAOYSA-N (4-boronophenyl)-[3-[(4-boronophenyl)methyl-dimethylazaniumyl]propyl]-dimethylazanium Chemical group B(O)(O)C1=CC=C(C[N+](CCC[N+](C)(C)C2=CC=C(C=C2)B(O)O)(C)C)C=C1 SCHLBXGBHOBSFT-UHFFFAOYSA-N 0.000 claims description 9
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 4
- 125000005587 carbonate group Chemical group 0.000 claims description 2
- 239000000499 gel Substances 0.000 abstract description 94
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 8
- 238000010586 diagram Methods 0.000 abstract description 3
- 238000013270 controlled release Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 32
- 239000000243 solution Substances 0.000 description 31
- 239000000203 mixture Substances 0.000 description 29
- 230000003914 insulin secretion Effects 0.000 description 22
- 238000011282 treatment Methods 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 14
- 239000000306 component Substances 0.000 description 14
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 13
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 11
- 230000003345 hyperglycaemic effect Effects 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 9
- 230000003647 oxidation Effects 0.000 description 9
- 238000007254 oxidation reaction Methods 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 201000001421 hyperglycemia Diseases 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 230000001019 normoglycemic effect Effects 0.000 description 7
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 229940043267 rhodamine b Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- PDNOURKEZJZJNZ-UHFFFAOYSA-N [4-(bromomethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(CBr)C=C1 PDNOURKEZJZJNZ-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000013583 drug formulation Substances 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 4
- 230000004043 responsiveness Effects 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- GJKGAPPUXSSCFI-UHFFFAOYSA-N 2-Hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone Chemical compound CC(C)(O)C(=O)C1=CC=C(OCCO)C=C1 GJKGAPPUXSSCFI-UHFFFAOYSA-N 0.000 description 3
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000005586 carbonic acid group Chemical group 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000001610 euglycemic effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000001879 gelation Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- DMQSHEKGGUOYJS-UHFFFAOYSA-N n,n,n',n'-tetramethylpropane-1,3-diamine Chemical compound CN(C)CCCN(C)C DMQSHEKGGUOYJS-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000000541 pulsatile effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 231100000057 systemic toxicity Toxicity 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 101100029848 Arabidopsis thaliana PIP1-2 gene Proteins 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- 238000012288 TUNEL assay Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003592 biomimetic effect Effects 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001142 circular dichroism spectrum Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 229960003681 gluconolactone Drugs 0.000 description 2
- 102000036202 glucose binding proteins Human genes 0.000 description 2
- 108091011004 glucose binding proteins Proteins 0.000 description 2
- 238000007446 glucose tolerance test Methods 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- DCUFMVPCXCSVNP-UHFFFAOYSA-N methacrylic anhydride Chemical compound CC(=C)C(=O)OC(=O)C(C)=C DCUFMVPCXCSVNP-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000002824 peroxisome Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- WVLBCYQITXONBZ-UHFFFAOYSA-N trimethyl phosphate Chemical compound COP(=O)(OC)OC WVLBCYQITXONBZ-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- IOVXUFGSHVQCRB-UHFFFAOYSA-N 4-(hydroxymethylidene)cyclohexa-1,5-dien-1-ol Chemical compound OC=C1CC=C(C=C1)O IOVXUFGSHVQCRB-UHFFFAOYSA-N 0.000 description 1
- SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 101710195300 Peroxisomal catalase Proteins 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- PZRPBPMLSSNFOM-UHFFFAOYSA-N [4-(hydroxymethyl)phenyl]boronic acid Chemical compound OCC1=CC=C(B(O)O)C=C1 PZRPBPMLSSNFOM-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 238000012644 addition polymerization Methods 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 229920005603 alternating copolymer Polymers 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 108700022423 fluorescein-isothiocyanated- insulin Proteins 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940046732 interleukin inhibitors Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000001254 matrix assisted laser desorption--ionisation time-of-flight mass spectrum Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 239000003076 neurotropic agent Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- OJPNKYLDSDFUPG-UHFFFAOYSA-N p-quinomethane Chemical compound C=C1C=CC(=O)C=C1 OJPNKYLDSDFUPG-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000111 poly(butyric acid) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001306 poly(lactide-co-caprolactone) Polymers 0.000 description 1
- 238000012643 polycondensation polymerization Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000005956 quaternization reaction Methods 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6955—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a plaster, a bandage, a dressing or a patch
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01006—Catalase (1.11.1.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0061—Methods for using microneedles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
- C12Y101/03004—Glucose oxidase (1.1.3.4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Description
本願は、2016年12月5日に出願された米国仮特許出願第62/430,260号の利益を主張し、その開示は、参照により本明細書に明示的に組み込まれる。
それぞれが基部及び先端部を有する複数のマイクロニードルと、
マイクロニードルの基部が取り付けられている基材と、を含む、マイクロニードルパッチが、本明細書に開示され、
マイクロニードルは、
第1の過酸化物感受性リンカーで架橋された第1のポリ(ビニルアルコール)(PVA)ポリマーと、
第1のナノゲル内に封入された過酸化物除去酵素であって、第1のナノゲルは、第1のPVAポリマーに埋め込まれている、過酸化物除去酵素と、を含む、
シェルと、
第2の過酸化物感受性リンカーで架橋された第2のポリ(ビニルアルコール)(PVA)ポリマーと、
第2のナノゲル内に封入されたグルコース応答性物質であって、第2のナノゲルは、第2のPVAポリマーに埋め込まれている、グルコース応答性物質と、
治療薬であって、治療薬は、第3の過酸化物感受性リンカーを用いて第2のPVAポリマーに共有結合している、治療薬と、を含む、
コアと、を含む。
高血糖レベルのグルコースの存在下でマイクロニードルパッチから治療薬を放出することと、を含む、被験体に治療薬を送達する方法が、本明細書に開示されている。
用語
マイクロニードル装置(パッチ)
それぞれが基部及び先端部を有する複数のマイクロニードルと、
マイクロニードルの基部が取り付けられている基材と、を含む、マイクロニードルパッチが、本明細書に開示され、
マイクロニードルは、
第1の過酸化物感受性リンカーで架橋された第1のポリ(ビニルアルコール)(PVA)ポリマーと、
第1のナノゲル内に封入された過酸化物除去酵素であって、第1のナノゲルは、第1のPVAポリマーに埋め込まれている、過酸化物除去酵素と、を含む、
シェルと、
第2の過酸化物感受性リンカーで架橋された第2のポリ(ビニルアルコール)(PVA)ポリマーと、
第2のナノゲル内に封入されたグルコース応答性物質であって、第2のナノゲルは、第2のPVAポリマーに埋め込まれている、グルコース応答性物質と、
治療薬であって、治療薬は、第3の過酸化物感受性リンカーを用いて第2のPVAポリマーに共有結合している、治療薬と、を含む、
コアと、を含む。
それぞれが基部及び先端部を有する複数のマイクロニードルと、
マイクロニードルの基部が付着又は一体化されている基材と、を含む、被験体の生物学的障壁を越えて物質を輸送するための装置が、本明細書に開示され、
マイクロニードルは、
第1の過酸化物感受性リンカーで架橋された第1のポリ(ビニルアルコール)(PVA)ポリマーと、
第1のナノゲル内に封入された過酸化物除去酵素であって、第1のナノゲルは、第1のPVAポリマーに埋め込まれている、過酸化物除去酵素と、を含む、
シェルと、
第2の過酸化物感受性リンカーで架橋された第2のポリ(ビニルアルコール)(PVA)ポリマーと、
第2のナノゲル内に封入されたグルコース応答性物質であって、第2のナノゲルは、第2のPVAポリマーに埋め込まれている、グルコース応答性物質と、
治療薬であって、治療薬は、第3の過酸化物感受性リンカーを用いて第2のPVAポリマーに共有結合している、治療薬と、を含む、
コアと、を含む。
それぞれが基部及び先端部を有する複数のマイクロニードルと、
マイクロニードルの基部が付着又は一体化されている基材と、を含む、生物学的障壁を越えて治療薬(例えば、インスリン)を送達するための部品のキットが、本明細書に開示され、
マイクロニードルは、
第1の過酸化物感受性リンカーで架橋された第1のポリ(ビニルアルコール)(PVA)ポリマーと、
第1のナノゲル内に封入された過酸化物除去酵素であって、第1のナノゲルは、第1のPVAポリマーに埋め込まれている、過酸化物除去酵素と、を含む、
シェルと、
第2の過酸化物感受性リンカーで架橋された第2のポリ(ビニルアルコール)(PVA)ポリマーと、
第2のナノゲル内に封入されたグルコース応答性物質であって、第2のナノゲルは、第2のPVAポリマーに埋め込まれている、グルコース応答性物質と、
治療薬であって、治療薬は、第3の過酸化物感受性リンカーを用いて第2のPVAポリマーに共有結合している、治療薬と、を含む、
コアと、を含む。
治療方法
治療を必要とする被験体にマイクロニードルパッチを投与することであって、マイクロニードルパッチは、
それぞれが基部及び先端部を有する複数のマイクロニードルと、
マイクロニードルの基部が取り付けられている基材と、を含む、マイクロニードルパッチであって、
マイクロニードルは、
第1の過酸化物感受性リンカーで架橋された第1のポリ(ビニルアルコール)(PVA)ポリマーと、
第1のナノゲル内に封入された過酸化物除去酵素であって、第1のナノゲルは、第1のPVAポリマーに埋め込まれている、過酸化物除去酵素と、を含む、
シェルと、
第2の過酸化物感受性リンカーで架橋された第2のポリ(ビニルアルコール)(PVA)ポリマーと、
第2のナノゲル内に封入されたグルコース応答性物質であって、第2のナノゲルは、第2のPVAポリマーに埋め込まれている、グルコース応答性物質と、
治療薬であって、治療薬は、第3の過酸化物感受性リンカーを用いて第2のPVAポリマーに共有結合している、治療薬と、を含む、
コアと、を含む、ことと、
高血糖レベルのグルコースの存在下でマイクロニードルパッチから治療薬を放出することと、を含む、被験体に治療薬を送達する方法が、本明細書に開示されている。
マイクロニードルパッチを被験体に提供することを含む、治療を必要とする被験体において疾患を治療するための方法もまた本明細書に開示され、マイクロニードルパッチは、
それぞれが基部及び先端部を有する複数のマイクロニードルと、
マイクロニードルの基部が取り付けられている基材と、を含み、
マイクロニードルは、
第1の過酸化物感受性リンカーで架橋された第1のポリ(ビニルアルコール)(PVA)ポリマーと、
第1のナノゲル内に封入された過酸化物除去酵素であって、第1のナノゲルは、第1のPVAポリマーに埋め込まれている、過酸化物除去酵素と、を含む、
シェルと、
第2の過酸化物感受性リンカーで架橋された第2のポリ(ビニルアルコール)(PVA)ポリマーと、
第2のナノゲル内に封入されたグルコース応答性物質であって、第2のナノゲルは、第2のPVAポリマーに埋め込まれている、グルコース応答性物質と、
治療薬であって、治療薬は、第3の過酸化物感受性リンカーを用いて第2のPVAポリマーに共有結合している、治療薬と、を含む、
コアと、を含む。
マイクロニードルパッチを被験体に提供することであって、マイクロニードルパッチは、
それぞれが基部及び先端部を有する複数のマイクロニードルと、
マイクロニードルの基部が取り付けられている基材と、を含み、
マイクロニードルは、
第1の過酸化物感受性リンカーで架橋された第1のポリ(ビニルアルコール)(PVA)ポリマーと、
第1のナノゲル内に封入された過酸化物除去酵素であって、第1のナノゲルは、第1のPVAポリマーに埋め込まれている、過酸化物除去酵素と、を含む、
シェルと、
第2の過酸化物感受性リンカーで架橋された第2のポリ(ビニルアルコール)(PVA)ポリマーと、
第2のナノゲル内に封入されたグルコース応答性物質であって、第2のナノゲルは、第2のPVAポリマーに埋め込まれている、グルコース応答性物質と、
治療薬であって、治療薬は、第3の過酸化物感受性リンカーを用いて前記第2のPVAポリマーに共有結合している、治療薬と、を含む、
コアと、を含む、ことと、
マイクロニードルを生物学的障壁に挿入し、高血糖レベルのグルコースが存在することにより治療薬をマイクロニードルパッチから放出することと、を含む、治療を必要とする被験体において疾患を治療するための方法もまた本明細書に開示されている。
結果
材料
方法
参考文献
[4]E.Cengiz,J.L.Sherr,S.A.Weinzimer,W.V.Tamborlane,Expert Rev Med Devices 2011,8,449.
[25]a)O.Olatunji,D.B.Das,M.J.Garland,L.Belaid,R.F.Donnelly,Journal Of Pharmaceutical Sciences 2013,102,1209;b)S.P.Davis,B.J.Landis,Z.H.Adams,M.G.Allen,M.R.Prausnitz,J Biomech 2004,37,1155.
Claims (21)
- それぞれが基部及び先端部を有する複数のマイクロニードルと、
前記マイクロニードルの前記基部が取り付けられている基材と、を含む、マイクロニードルパッチであって、
前記マイクロニードルは、
第1の過酸化物感受性リンカーで架橋された第1のポリ(ビニルアルコール)(PVA)ポリマーと、
第1のナノゲル内に封入された過酸化物除去酵素であって、前記第1のナノゲルは、前記第1のPVAポリマーに埋め込まれている、過酸化物除去酵素と、を含む、
シェルと、
第2の過酸化物感受性リンカーで架橋された第2のポリ(ビニルアルコール)(PVA)ポリマーと、
第2のナノゲル内に封入されたグルコース応答性物質であって、前記第2のナノゲルは、前記第2のPVAポリマーに埋め込まれている、グルコース応答性物質と、
治療薬であって、前記治療薬は、第3の過酸化物感受性リンカーを用いて前記第2のPVAポリマーに共有結合している、治療薬と、を含む、
コアと、を含む、マイクロニードルパッチ。 - 前記第1の過酸化物感受性リンカーは、ボロン酸エステルを含む、請求項1に記載のマイクロニードルパッチ。
- 前記第1の過酸化物感受性リンカーは、N1−(4−ボロノベンジル)−N3−(4−ボロノフェニル)−N1,N1,N3,N3−テトラメチルプロパン−1,3−ジアミニウム(TSPBA)である、請求項1又は2に記載のマイクロニードルパッチ。
- 前記第2の過酸化物感受性リンカーは、ボロン酸エステルを含む、請求項1〜3のいずれか一項に記載のマイクロニードルパッチ。
- 前記第2の過酸化物感受性リンカーは、N1−(4−ボロノベンジル)−N3−(4−ボロノフェニル)−N1,N1,N3,N3−テトラメチルプロパン−1,3−ジアミニウム(TSPBA)である、請求項1〜4のいずれか一項に記載のマイクロニードルパッチ。
- 前記第3の過酸化物感受性リンカーは、ボロン酸エステルを含む、請求項1〜5のいずれか一項に記載のマイクロニードルパッチ。
- 前記第3の過酸化物感受性リンカーは、炭酸=4−ニトロフェニル=(4,4,5,5−テトラメチル−1,3,2−ジオキサボロラン−2−イル)ベンジル(NBC)である、請求項1〜6のいずれか一項に記載のマイクロニードルパッチ。
- 前記グルコース応答剤は、グルコースオキシダーゼを含む、請求項1〜7のいずれか一項に記載のマイクロニードルパッチ。
- 前記過酸化物除去酵素は、カタラーゼである、請求項1〜8のいずれか一項に記載のマイクロニードルパッチ。
- 前記治療薬は、インスリンである、請求項1〜9のいずれか一項に記載のマイクロニードルパッチ。
- 前記マイクロニードルは、ヒアルロン酸(HA)をさらに含む、請求項1〜10のいずれか一項に記載のマイクロニードルパッチ。
- 請求項1〜11のいずれか一項に記載のマイクロニードルパッチを前記被験体に投与することと、
高血糖レベルのグルコースの存在下で前記マイクロニードルパッチから前記治療薬を放出することと、を含む、治療薬を被験体に送達する方法。 - 前記被験体は、糖尿病である、請求項12に記載の方法。
- 前記グルコース応答剤は、高血糖レベルのグルコースへの曝露時に過酸化物を生成する、請求項12又は13に記載の方法。
- 前記方法は、前記過酸化物への曝露時に前記第1の過酸化物感受性リンカーを前記第1のPVAポリマーから脱離することをさらに含む、請求項12〜14のいずれかに一項に記載の方法。
- 前記方法は、前記過酸化物への曝露時に前記第2の過酸化物感受性リンカーを前記第2のPVAポリマーから脱離することをさらに含む、請求項12〜15のいずれかに一項に記載の方法。
- 前記方法は、前記過酸化物への曝露時に前記第3の過酸化物感受性リンカーを前記第2のPVAポリマーから脱離することをさらに含む、請求項12〜16のいずれかに一項に記載の方法。
- 前記第3の過酸化物感受性リンカーを前記第2のPVAポリマーから脱離することで、前記マイクロニードルパッチから前記治療薬を放出する、請求項17に記載の方法。
- 前記方法は、血糖値を低下させることをさらに含む、請求項12〜18のいずれかに一項に記載の方法。
- 前記治療薬は、インスリンを含む、請求項12〜19のいずれか一項に記載の方法。
- 前記方法は、低血糖症を引き起こす前に前記治療薬の放出を終了することをさらに含む、請求項12〜20のいずれか一項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662430260P | 2016-12-05 | 2016-12-05 | |
US62/430,260 | 2016-12-05 | ||
PCT/US2017/064723 WO2018106696A1 (en) | 2016-12-05 | 2017-12-05 | Core-shell microneedle devices and uses thereof |
Publications (4)
Publication Number | Publication Date |
---|---|
JP2020512283A true JP2020512283A (ja) | 2020-04-23 |
JP2020512283A5 JP2020512283A5 (ja) | 2020-12-03 |
JPWO2018106696A5 JPWO2018106696A5 (ja) | 2022-02-09 |
JP7232526B2 JP7232526B2 (ja) | 2023-03-03 |
Family
ID=62491316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019529985A Active JP7232526B2 (ja) | 2016-12-05 | 2017-12-05 | コアシェル型マイクロニードル装置及びその使用 |
Country Status (7)
Country | Link |
---|---|
US (2) | US11697007B2 (ja) |
EP (2) | EP3799865B1 (ja) |
JP (1) | JP7232526B2 (ja) |
CN (1) | CN110167624B (ja) |
CA (1) | CA3045882A1 (ja) |
DK (1) | DK3548135T3 (ja) |
WO (1) | WO2018106696A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019143293A1 (en) * | 2018-01-16 | 2019-07-25 | Nanyang Technological University | Self-implantable micro-drug-reservoirs for localized and controlled ocular drug delivery |
WO2019161272A1 (en) | 2018-02-15 | 2019-08-22 | North Carolina State University | Synthesis of micron and nanoscale carbon spheres and structures using hydrothemal carbonization |
EP3765029A4 (en) * | 2018-04-13 | 2021-12-08 | North Carolina State University | ROS-RESPONSIVE MICRON NEEDLE PLASTER FOR ACNE VULGARIS TREATMENT |
US20210213266A1 (en) * | 2018-08-24 | 2021-07-15 | North Carolina State University | Cardiac Cell Microneedle Patch for Treating Heart Diseases |
KR20210049864A (ko) * | 2018-08-24 | 2021-05-06 | 노쓰 캐롤라이나 스테이트 유니버시티 | 폐루프 인슐린 전달을 위한 포도당 반응성 매트릭스를 갖는 마이크로니들 배열 패치 |
WO2020060495A1 (en) * | 2018-09-20 | 2020-03-26 | Singapore Health Services Pte Ltd | Conductive microneedle patch for active agent delivery |
CN109675185A (zh) * | 2019-01-02 | 2019-04-26 | 浙江大学 | 一种苯硼酸水凝胶基糖敏微针贴及其制备方法 |
JP2021153914A (ja) * | 2020-03-27 | 2021-10-07 | 国立大学法人 東京医科歯科大学 | 薬剤送達デバイスおよびその製造方法 |
CN117159443B (zh) * | 2023-10-19 | 2024-04-19 | 暨南大学 | 原位超分子凝胶微针贴片及其制备方法和应用 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005526009A (ja) * | 2001-12-02 | 2005-09-02 | ノボ ノルディスク アクティーゼルスカブ | 新規グルコース依存性インスリン |
JP2010540507A (ja) * | 2007-09-28 | 2010-12-24 | ザ クイーンズ ユニヴァーシティ オブ ベルファスト | 送達装置および方法 |
JP2011508786A (ja) * | 2008-01-04 | 2011-03-17 | バイオデル, インコーポレイテッド | 組織グルコースレベルの関数としてのインスリン放出のためのインスリン製剤 |
WO2013123492A2 (en) * | 2012-02-17 | 2013-08-22 | Massachusetts Institute Of Technology | Glucose-responsive microgels for closed loop insulin delivery |
WO2014113679A1 (en) * | 2013-01-18 | 2014-07-24 | The University Of North Carolina At Chapel Hill | High-throughput manufacturing of microneedles |
US20160157764A1 (en) * | 2014-12-03 | 2016-06-09 | IMAST scarl | Microneedle array device and method of making |
JP2016517885A (ja) * | 2013-04-30 | 2016-06-20 | マサチューセッツ インスティテュート オブ テクノロジー | 糖尿病を処置するための注射可能なナノネットワークゲル |
WO2016172320A1 (en) * | 2015-04-21 | 2016-10-27 | North Carolina State University Office Of Technology Transfer | Glucose-responsive insulin delivery system using hyoxia-sensitive nanocomposites |
WO2018085809A1 (en) * | 2016-11-07 | 2018-05-11 | North Carolina State University | Patch loaded with dual-sensitive vesicles for enhanced glucose-responsive insulin delivery |
WO2018106697A1 (en) * | 2016-12-05 | 2018-06-14 | North Carolina State University | H 2o 2-responsive nanoparticles and uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2742049A1 (en) * | 2008-10-31 | 2010-05-06 | The Brigham And Women's Hospital, Inc. | Vaccination with poxvirus vectors via mechanical epidermal disruption |
WO2016172554A1 (en) * | 2015-04-23 | 2016-10-27 | Carnegie Mellon University | Biosensor tattoos and uses therefor for biomarker monitoring |
-
2017
- 2017-12-05 CA CA3045882A patent/CA3045882A1/en not_active Abandoned
- 2017-12-05 CN CN201780081305.1A patent/CN110167624B/zh active Active
- 2017-12-05 DK DK17879565.4T patent/DK3548135T3/da active
- 2017-12-05 US US16/466,775 patent/US11697007B2/en active Active
- 2017-12-05 EP EP20205415.1A patent/EP3799865B1/en active Active
- 2017-12-05 EP EP17879565.4A patent/EP3548135B1/en active Active
- 2017-12-05 WO PCT/US2017/064723 patent/WO2018106696A1/en active Application Filing
- 2017-12-05 JP JP2019529985A patent/JP7232526B2/ja active Active
-
2023
- 2023-05-23 US US18/321,936 patent/US20230364402A1/en active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005526009A (ja) * | 2001-12-02 | 2005-09-02 | ノボ ノルディスク アクティーゼルスカブ | 新規グルコース依存性インスリン |
JP2010540507A (ja) * | 2007-09-28 | 2010-12-24 | ザ クイーンズ ユニヴァーシティ オブ ベルファスト | 送達装置および方法 |
JP2011508786A (ja) * | 2008-01-04 | 2011-03-17 | バイオデル, インコーポレイテッド | 組織グルコースレベルの関数としてのインスリン放出のためのインスリン製剤 |
WO2013123492A2 (en) * | 2012-02-17 | 2013-08-22 | Massachusetts Institute Of Technology | Glucose-responsive microgels for closed loop insulin delivery |
WO2014113679A1 (en) * | 2013-01-18 | 2014-07-24 | The University Of North Carolina At Chapel Hill | High-throughput manufacturing of microneedles |
JP2016517885A (ja) * | 2013-04-30 | 2016-06-20 | マサチューセッツ インスティテュート オブ テクノロジー | 糖尿病を処置するための注射可能なナノネットワークゲル |
US20160157764A1 (en) * | 2014-12-03 | 2016-06-09 | IMAST scarl | Microneedle array device and method of making |
WO2016172320A1 (en) * | 2015-04-21 | 2016-10-27 | North Carolina State University Office Of Technology Transfer | Glucose-responsive insulin delivery system using hyoxia-sensitive nanocomposites |
JP2018513874A (ja) * | 2015-04-21 | 2018-05-31 | ノース カロライナ ステート ユニバーシティNorth Carolina State University | 低酸素感受性ナノコンポジットを用いたグルコース応答性インスリン送達システム |
WO2018085809A1 (en) * | 2016-11-07 | 2018-05-11 | North Carolina State University | Patch loaded with dual-sensitive vesicles for enhanced glucose-responsive insulin delivery |
WO2018106697A1 (en) * | 2016-12-05 | 2018-06-14 | North Carolina State University | H 2o 2-responsive nanoparticles and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
US20230364402A1 (en) | 2023-11-16 |
EP3548135A1 (en) | 2019-10-09 |
EP3548135B1 (en) | 2021-10-13 |
EP3799865A1 (en) | 2021-04-07 |
US11697007B2 (en) | 2023-07-11 |
CA3045882A1 (en) | 2018-06-14 |
JP7232526B2 (ja) | 2023-03-03 |
WO2018106696A1 (en) | 2018-06-14 |
CN110167624A (zh) | 2019-08-23 |
EP3799865B1 (en) | 2022-06-15 |
CN110167624B (zh) | 2021-11-19 |
US20190351206A1 (en) | 2019-11-21 |
DK3548135T3 (da) | 2021-11-22 |
EP3548135A4 (en) | 2020-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7232526B2 (ja) | コアシェル型マイクロニードル装置及びその使用 | |
Kim et al. | Implantable powder-carrying microneedles for transdermal delivery of high-dose insulin with enhanced activity | |
Zhao et al. | pH and glucose dual-responsive injectable hydrogels with insulin and fibroblasts as bioactive dressings for diabetic wound healing | |
Yavuz et al. | Silk fibroin microneedle patches for the sustained release of levonorgestrel | |
Guo et al. | Responsive hydrogel-based microneedle dressing for diabetic wound healing | |
Chen et al. | Chitosan microneedle patches for sustained transdermal delivery of macromolecules | |
Xie et al. | Enhanced in vitro efficacy for inhibiting hypertrophic scar by bleomycin-loaded dissolving hyaluronic acid microneedles | |
US11351230B2 (en) | Patch loaded with dual-sensitive vesicles for enhanced glucose-responsive insulin delivery | |
Xue et al. | Flexible PEGDA-based microneedle patches with detachable PVP–CD arrowheads for transdermal drug delivery | |
Zhu et al. | Flexible polymeric patch based nanotherapeutics against non-cancer therapy | |
WO2018226160A1 (en) | Microneedle patch loaded with a fat browning agent and a method for preparing the same | |
CN111629746B (zh) | 具有超快响应的用于葡萄糖触发胰岛素递送的电荷可切换聚合物储库 | |
US20230381096A1 (en) | Core-shell microneedle patch for h2o2 and ph cascade-triggered insulin delivery | |
US20210244658A1 (en) | Microneedle-array patches with glucose-responsive matrix for closed-loop insulin delivery | |
US11331277B2 (en) | H2O2-responsive nanoparticles and uses thereof | |
WO2021066747A1 (en) | Self-administrable and implantable polymeric micro-lance shaped device for controlled and targeted delivery | |
You et al. | Ultrarapid‐Acting Microneedles for Immediate Delivery of Biotherapeutics | |
Liu et al. | Injectable smart stimuli-responsive hydrogels: pioneering advancements in biomedical applications | |
He et al. | A universal powder-laden crosslinked chitosan microneedle patch for high-dose controllable drug delivery | |
Azar et al. | Integration of polysaccharide electrospun nanofibers with microneedle arrays promotes wound regeneration: A review | |
Güngör et al. | Recent advances in biopolymer-based transdermal patches | |
Zhang | Bioresponsive Drug Delivery by Microneedle Patches | |
Gu et al. | H 2 O 2-responsive nanoparticles and uses thereof | |
Bhatnagar et al. | Protein-Based Microneedles for Drug and Vaccine Delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201022 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201022 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210720 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210803 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211029 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211222 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20220201 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220201 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220928 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230117 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230213 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7232526 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |